A Wake-Up Call: The Flu Season is Coming, and We Need to Do Better!
The flu can be more than just a bad cold – it can lead to serious complications, even death. Last year's flu season was particularly severe, with hospitalization rates the highest they've been in over a decade. But here's the kicker: a large percentage of those hospitalized hadn't been vaccinated. New data from the Centers for Disease Control and Prevention (CDC) is shedding light on what we can expect for the 2025-2026 flu season, and it's crucial to pay attention.
Let's dive into the key takeaways, including vaccine effectiveness, updated recommendations, and what you can do to protect yourself and your loved ones. Are the updated vaccine formulations and access points enough to turn the tide? The answer might surprise you.
The Ghost of Flu Seasons Past: What Happened in 2024-2025?
The 2024-2025 influenza season was a stark reminder of the flu's potential impact. CDC FluSurv-NET data revealed a cumulative hospitalization rate of 127.1 per 100,000 people. To put that in perspective, it was the highest rate since the 2010-2011 season! Hospitalization rates were significantly elevated across all age groups, with adults 75 years and older being hit the hardest (598.8 per 100,000).
And this is the part most people miss: the majority of those hospitalized (89.1%) had underlying medical conditions, making them even more vulnerable. While the severity of the season wasn't attributed to a more virulent flu strain, the high incidence exposed critical gaps in our prevention and treatment strategies.
Here's a troubling statistic: only 32.4% of hospitalized patients had received a flu vaccine. Furthermore, antiviral medication use was surprisingly low, especially among school-aged children (only 61.6% of those aged 5-17 received them). This highlights a significant opportunity to improve both vaccination rates and timely treatment.
Vaccine Effectiveness: How Well Did It Work?
Interim data from several US influenza vaccine-effectiveness networks (IVY, NVSN, US Flu VE, VISION) provided insights into how well the 2024-2025 vaccines performed. The results were mixed, but overall showed meaningful protection.
- Children (<18 years): The vaccines reduced outpatient visits by 32%-60% and hospitalizations by 63%-78%. Protection was strongest against the A(H1N1)pdm09 strain.
- Adults (≥18 years): The vaccines reduced outpatient visits by 36%-54% and hospitalizations by 41%-55%. Vaccine effectiveness varied somewhat across age groups, with older adults (≥65 years) showing slightly lower protection in some estimates.
Despite these encouraging figures, vaccination coverage among those tested remained relatively low, ranging from 20-40% in children and around one-third in adults. This underscores the need for continued efforts to improve vaccine uptake.
Fortunately, most sequenced viruses were well-matched to the vaccine strains, including the circulating A(H3N2) and A(H1N1)pdm09 clades. This suggests that the vaccines were, on the whole, targeting the right viruses.
What's New for 2025-2026: Updated Recommendations and Formulations
Learning from the previous season, the CDC has introduced several key changes for the 2025-2026 flu season, aiming to simplify vaccination and improve access:
- Universal Thimerosal-Free, Single-Dose Formulations: All US flu vaccines for this season are now available in single-dose, thimerosal-free formulations. This aims to address concerns about thimerosal (a mercury-based preservative) and simplify administration.
- Expanded Access to FluMist: The nasal spray flu vaccine, FluMist, is now approved for self-administration or administration by a caregiver. This could make it easier for families to vaccinate their children.
- Expanded FluBlok Age Indication: The FluBlok vaccine, a recombinant influenza vaccine, is now approved for individuals aged 9 years and older.
These changes, coupled with a stable vaccine supply (manufacturers expect up to 154 million doses), are designed to overcome barriers and boost vaccination rates across all age groups. Vaccination remains free or low cost through insurance coverage, community clinics, HRSA-supported centers, and the Vaccines for Children program.
What the Early Data Shows for 2025-2026
Early surveillance data from the CDC's Week 47 FluView report offers a glimpse into the current season:
- Low Activity: Nationally, influenza activity remains low, but is showing signs of increasing. About 5% of respiratory specimens tested positive for influenza, and 2.5% of outpatient visits were for respiratory illness.
- H3N2 Dominance: Among subtyped influenza A specimens, A(H3N2) viruses are currently predominant, accounting for over 80% of cases. A(H1N1)pdm09 viruses make up the remaining portion.
- Antigenic Match: Antigenic analyses indicate a strong similarity between the vaccine components and circulating A(H1N1)pdm09 and B/Victoria viruses. However, the match for A(H3N2) is only partial, with about 33% of viruses showing good recognition by antisera to the updated vaccine component.
But here's where it gets controversial... A partial match doesn't mean the vaccine is ineffective against H3N2, but it does suggest that the level of protection might be lower compared to the other strains. This is something to watch closely as the season progresses.
CDC's Updated Recommendations for 2025-2026
The CDC has reaffirmed its recommendation for annual influenza vaccination for everyone 6 months and older. The 2025-2026 vaccines are trivalent, targeting A(H1N1)pdm09, A(H3N2), and B/Victoria-lineage viruses. The specific strains included in the vaccines vary slightly depending on whether they are egg-based or cell-based/recombinant.
Implications for You: What Should You Do?
Given last year's high burden, moderate vaccine effectiveness, updated recommendations, and early-season trends, the message is clear: vaccination remains the most effective way to reduce your risk of getting sick and being hospitalized with the flu. Early antiviral treatment is also crucial for those at high risk or who are hospitalized.
Remember those persistent gaps in vaccination coverage? That means we all need to do our part. Talk to your doctor, visit a pharmacy, or check out community vaccination clinics to get your flu shot.
Also, remember to stay informed! Clinicians should closely monitor patients with severe respiratory illness, consider the possibility of zoonotic exposures (especially with H5 virus activity), and follow updates from reputable sources like the NFID, IDSA, and CDC throughout the flu season.
Let's Talk About It:
What are your thoughts on the updated flu vaccine recommendations? Do you think the changes will lead to higher vaccination rates? Are you concerned about the partial match between the vaccine and the dominant H3N2 strain? Share your opinions and experiences in the comments below!
